Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities?

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages 1728-1735

  Postel Vinay, Sophie ^a,b,c   Gomez Roca, Carlos ^a,b,c   Molife, L Rhoda ^a,b,c   Anghan, Bhavesh ^a,b,c   Levy, Antonin ^a,b,c   Judson, Ian ^a,b,c   De Bono, Johann ^a,b,c   Soria, Jean Charles ^a,b,c   Kaye, Stan ^a,b,c   Paoletti, Xavier ^a,b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSERM U900   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE TUMOR; RISK FACTOR; SARCOMA; SKIN TOXICITY; THORAX TUMOR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; KIDNEY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; SKIN; TIME FACTORS;

EID: 79955617684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.9236     Document Type: Article

References (33)

1. Gelmon KA, Eisenhauer EA, Harris AL, et al: Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 91:1281-1287, 1999 (Pubitemid 29387569)
2. Stadler WM, Ratain MJ: Development of targetbased antineoplastic agents. Invest New Drugs 18:7-16, 2000
3. Ratain MJ, Stadler WM: Clinical trial designs for cytostatic agents. J Clin Oncol 19:3154-3155, 2001
4. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
5. Booth CM, Calvert AH, Giaccone G, et al: Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:19-24, 2008 (Pubitemid 350256933)
6. Duran I, Hotte SJ, Hirte H, et al: Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13:4849-4857, 2007 (Pubitemid 47294792)
7. Sleijfer S, Wiemer E: Dose selection in phase I studies: Why we should always go for the top. J Clin Oncol 26:1576-1578, 2008
8. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
9. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 96:990-997, 2004 (Pubitemid 39162641)
10. Kiura K, Nakagawa K, Shinkai T, et al: A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 3:386-393, 2008 (Pubitemid 351489479)
11. Tanaka C, O'Reilly T, Kovarik JM, et al: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602, 2008
12. O'Donnell A, Faivre S, Burris HA 3rd, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
13. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
14. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001 (Pubitemid 33055745)
15. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005 (Pubitemid 41132637)
16. Rini BI, Wilding G, Hudes G, et al: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468, 2009
17. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714, 2008
18. Paoletti X, Baron B, Schöffski P, et al: Using the continual reassessment method: Lessons learned from an EORTC phase I dose finding study. Eur J Cancer 42:1362-1368, 2006 (Pubitemid 43922405)
19. Le Tourneau C, Lee JJ, Siu LL: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720, 2009
20. Koyfman SA, Agrawal M, Garrett-Mayer E, et al: Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 110:1115-1124, 2007 (Pubitemid 47312878)
21. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
22. Roberts TG Jr, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130-2140, 2004 (Pubitemid 39435104)
23. Alam SM, Fehrmann RS, Olmos D, et al: Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A singlecenter experience. J Clin Oncol 28:208s, 2010 (suppl; abstr 2519)
24. Di Lorenzo G, Cartenì G, Autorino R, et al: Phase II study of sorafenib in patients with sunitinibrefractory metastatic renal cell cancer. J Clin Oncol 27:4469-4474, 2009
25. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997 (Pubitemid 27337928)
26. Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005 (Pubitemid 41060823)
27. Awada A, Hendlisz A, Gil T, et al: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855-1861, 2005
28. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005 (Pubitemid 46202316)
29. Moore M, Hirte HW, Siu L, et al: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688-1694, 2005 (Pubitemid 41510145)
30. Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28:S24-S31, 2009 (suppl 1)
31. Gazdar AF: Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361:1018-1020, 2009
32. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003 (Pubitemid 36910021)
33. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)